|Articles|February 1, 2000

February 2000
Volume 6
Issue 2

Barriers to Using Cost-Effectiveness Analysis in Managed Cae Decision Making

Author(s)Lisa A. Prosser, MS, Jeffrey P. Koplan, MD, MPH, Peter J. Neumann, ScD

Download PDF: Barriers to Using Cost-Effectiveness Analysis in Managed Cae Decision Making

Articles in this issue

over 26 years ago

Article

Asking Women to See Nurses or Unfamiliar Physicians as Part of Primary Care Redesign

over 26 years ago

Article

Cost of Treating Influenza in Emergency Department and Hospital Settings

over 26 years ago

Article

Hospital Resource Consumption in Patients with Diabetes and Multivessel Coronary Disease Undergoing Revascularization

over 26 years ago

Article

Ischemic Stroke: Acute Management and Secondary Prevention

over 26 years ago

Article

Is Cost-Effectiveness Modeling Useful?

over 26 years ago

Article

Cost-Effectiveness Analysis under Managed Care: Not Yet Ready for Prime Time?

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

ByThomas W. Martens, MD,Bimal V. Patel, PharmD, MS,Sharon M. Wang, PharmD, MS,Laurel H. Messer, PhD, MPH, RN, CDCES, BC-ADM,Jordan E. Pinsker, MD,Daniel C. Malone, PhD, RPh,Miranda R. Polin, MS, BS,Diana I. Brixner, PhD, RPh,Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES,Osagie Ebekozien, MD, MPH

July 23rd 2026

Geographical Access to Preferred Pharmacies in Medicare Part D

ByPinka Chatterji, PhD,Yiran Han, PhD,Chun-Yu Ho, PhD

July 22nd 2026

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

ByEmily A. Gadbois, PhD,Jennifer Bunker, MPH,Marguerite Daus, PhD, RN,Jamie M. Smith, PhD, RN,Emily Buss, MSN, RN,Christine D. Jones, MD, MS,Kali S. Thomas, PhD, MA

July 16th 2026

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

ByHeather L. Taylor, MPH, LDH,Ann M. Holmes, PhD,Nir Menachemi, PhD, MPH,Justin Blackburn, PhD

July 10th 2026

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

ByChristopher Scannell, MD, PhD,John A. Romley, PhD,Rebecca Myerson, PhD,Dana Goldman, PhD,Dima Mazen Qato, PharmD, PhD, MPH

July 9th 2026

Barriers to Using Cost-Effectiveness Analysis in Managed Cae Decision Making

Articles in this issue

Related Content

Impact of Automated Insulin Delivery on Type 2 Diabetes Measures

Geographical Access to Preferred Pharmacies in Medicare Part D

Roles and Priorities Guiding Medicare Advantage Postacute Home Health Referrals

Reply to Letter Regarding “Preventive Dental Care and Overall Medical Expenditures”

Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Trending on AJMC

FDA Panel Backs 6 Peptides for Compounding

Teclistamab-Talquetamab Combo Cuts Myeloma Progression Risk by 89%

Oncology Leaders Call for Greater Collaboration to Advance Precision Medicine, Innovative Cancer Care

FAQs: Cyclospora Recovery, Treatment, and Outbreak Prevention Strategies

Study Shows Potential for Low-Dose CAR T, With Implications for Increased Access